Pharmaceuticals, Biotechnology and Life Sciences
Data from Phase III EXPAND trial, continue to build on existing clinical evidence that Mayzent has significant impact on reducing the risk of disease progression, including physical disability and cognitive decline for patients with SPMS.
The global multiple sclerosis drugs market was worth $20.83 billion in 2019. North America is expected to be the largest region in the forecast period.
Biogen and Alkermes got approval from USFDA for Vumertiy, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Induction of Antigen-Specific Immune Tolerance Using Proprietary Technology Represents Novel, Targeted Treatment Modality for Autoimmune Diseases CAMBRIDGE, Mass. & LAUSANNE,…
Merck, a leading science and technology company, today announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).
Swedish biotech company focused on autoimmune diseases, Cyxone is testing its drug candidate T20K, its first-in-human, phase I, clinical trial, for the treatment of multiple sclerosis (MS).
Novartis on Wednesday said that it got approval from the FDA for Mayzent for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.
Novartis’s Gilenya became the first and only oral disease-modifying treatment for young patients with relapsing-remitting forms of multiple sclerosis (RRMS),…
Alkermes has received a $50 million payment from Biogen after it reviewed the preliminary gastrointestinal tolerability data from the ongoing…